Loading...
Global Access to Multiple Myeloma Therapies
Atallah, Rawan Shatnawi, Yara Ayoobkhan, Fathima Shehnaz Islam Saif, Md Saiful Naeem, Menahil Logan, Emerson Mushtaq, Muhammad Umair Rana, Shabeeha Mammadzadeh, Aytaj Hashmi, Shahrukh K.
Atallah, Rawan
Shatnawi, Yara
Ayoobkhan, Fathima Shehnaz
Islam Saif, Md Saiful
Naeem, Menahil
Logan, Emerson
Mushtaq, Muhammad Umair
Rana, Shabeeha
Mammadzadeh, Aytaj
Hashmi, Shahrukh K.
Author
Atallah, Rawan
Shatnawi, Yara
Ayoobkhan, Fathima Shehnaz
Islam Saif, Md Saiful
Naeem, Menahil
Logan, Emerson
Mushtaq, Muhammad Umair
Rana, Shabeeha
Mammadzadeh, Aytaj
Hashmi, Shahrukh K.
Mohamed, Benlazar
Desai, Nihar
Carneiro, Thiago Xavier
Popat, Rakesh
McGuirk, Joseph P.
Atrash, Shebli
Mahmoudjafari, Zahra
Hammad, Nada
Anwer, Faiz
Ahmed, Nausheen
Abdallah, Al-Ola
Shatnawi, Yara
Ayoobkhan, Fathima Shehnaz
Islam Saif, Md Saiful
Naeem, Menahil
Logan, Emerson
Mushtaq, Muhammad Umair
Rana, Shabeeha
Mammadzadeh, Aytaj
Hashmi, Shahrukh K.
Mohamed, Benlazar
Desai, Nihar
Carneiro, Thiago Xavier
Popat, Rakesh
McGuirk, Joseph P.
Atrash, Shebli
Mahmoudjafari, Zahra
Hammad, Nada
Anwer, Faiz
Ahmed, Nausheen
Abdallah, Al-Ola
Supervisor
Department
Computer Vision
Embargo End Date
Type
Journal article
Date
2025
License
Language
English
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Purpose
Initial reports indicate that access to contemporary therapies currently used in North America for the treatment of multiple myeloma (MM) varies internationally. No studies have quantitatively reported the extent of disparities in the access to MM therapies worldwide, with a goal to investigate access to MM therapies and barriers globally.
Methods
From June 18 to July 15, 2023, an electronic survey was distributed to 176 oncologists treating MM outside the United States. MM drugs were categorized by accessibility, with the cutoff for adequate access set at 60% of respondents affirming easy/moderate access.
Results
Ninety-five (54%) respondents from 33 countries completed the survey. Fifty-one percent of the respondents were from university-based academic programs, and 17% of the responders treated only plasma cell disorders. Most respondents had adequate access to noncellular MM therapies, except for isatuximab, ixazomib, selinexor, and elotuzumab. Among the cellular therapies, 17% had access to Chimeric Antigen Receptor T-cell therapy, whereas 23% had access to approved T-cell engagers (TCEs). Financial stress on patients and health care systems has emerged as a primary barrier to global inaccessibility of treatment drugs.
Conclusion
Global access to novel MM therapies remains challenging, and we have identified barriers and suggested strategies to bridge this gap.
Citation
R. Atallah et al., “Global Access to Multiple Myeloma Therapies,” JCO Glob Oncol, no. 11, Jun. 2025, doi: 10.1200/GO-24-00441.
Source
JCO Global Oncology
Conference
Keywords
Subjects
Source
Publisher
Lippincott Williams & Wilkins